Comparing SG&A Efficiency: Summit Therapeutics Inc. vs. MannKind Corporation

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, MannKind Corporation and Summit Therapeutics Inc. have demonstrated contrasting approaches to SG&A cost management.

MannKind Corporation's SG&A Trends

MannKind Corporation has consistently reported higher SG&A expenses, averaging around $78 million annually. Notably, in 2015, their SG&A costs peaked at approximately $108 million, reflecting a strategic investment phase. However, by 2023, they managed to reduce this figure by about 13% to $94 million.

Summit Therapeutics Inc.'s Cost Control

In contrast, Summit Therapeutics Inc. has maintained a more conservative SG&A expenditure, averaging $16 million per year. Their expenses have steadily increased, reaching $28 million in 2023, marking a 315% rise since 2014. This growth aligns with their expansion strategy.

Both companies exhibit distinct financial strategies, with MannKind focusing on aggressive spending and Summit on gradual growth.